Allogene Therapeutics (ALLO) News and press releases

Analyst Ratings for Allogene Therapeutics

25 Sep 23

Analyst Ratings

JP Morgan Maintains Overweight on Allogene Therapeutics, Lowers Price Target to $9

25 Sep 23

News, Price Target, Analyst Ratings

JP Morgan analyst Brian Cheng maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight and lowers the price target from $11 to $9.

Stocks That Hit 52-Week Lows On Thursday

21 Sep 23

Options

During the session on Thursday, 461 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

14 Aug 23

Options

During Monday's session, 201 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

8 Aug 23

Options

During Tuesday's trading, 188 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

7 Aug 23

Options

On Monday, 149 companies reached new 52-week lows.

HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $23 Price Target

7 Aug 23

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $23 price target.

Oppenheimer Reiterates Outperform on Allogene Therapeutics, Maintains $28 Price Target

3 Aug 23

News, Price Target, Reiteration, Analyst Ratings

Oppenheimer analyst Mark Breidenbach reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $28 price target.

EF Hutton Reiterates Buy on Allogene Therapeutics, Maintains $15 Price Target

3 Aug 23

News, Price Target, Reiteration, Analyst Ratings

EF Hutton analyst Tony Butler reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $15 price target.

Allogene Therapeutics Q2 EPS $(0.53) Beats $(0.59) Estimate, Sales $44.00K Miss $70.00K Estimate

2 Aug 23

Earnings, News

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.59) by 10.17 percent. This is a 1.92 percent decrease over losses of $(0.52) per share

Earnings Outlook For Allogene Therapeutics

1 Aug 23

Earnings

Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18

12 Jul 23

News, Price Target, Analyst Ratings

Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $20 to $18.

Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.

5 Sep 23

Press Releases

Two premier research analysts bring decades of experience covering the biotechnology industry NEW YORK, Sept. 5, 2023 /PRNewswire/ -- Cantor Fitzgerald, L.P., ("Cantor") a leading global financial services

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

2 Aug 23

Earnings, Press Releases

Presented Long-Term Data for an Allogeneic CD19 CAR T Product Candidate in Relapsed/Refractory Large B Cell Lymphoma (LBCL) at the American Society of Clinical Oncology (ASCO) Annual Meeting and International Conference